Protein kinase CK2-dependent regulation of p53 function: Evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable

Molecular and Cellular Biochemistry

Volumn 191, Issue 1-2, 1999, Pages 187-199

  McKendrick, Linda ^a   Milne, Diane ^a   Meek, David ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Centrosome; Ck2; Dephosphorylation; p53; Subcellular localisation

Indexed keywords

CASEIN KINASE II; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN P53; RECOMBINANT PROTEIN; SERINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL CYCLE; CELL NUCLEUS; CENTROSOME; CONTROLLED STUDY; CYTOPLASM; DEPHOSPHORYLATION; DNA BINDING; DNA DAMAGE; ENZYME SUBUNIT; FIBROBLAST; IMMUNOFLUORESCENCE TEST; MICROTUBULE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; RENATURATION; TRANSCRIPTION REGULATION; ULTRAVIOLET IRRADIATION;

ANIMALIA; MURINAE;

EID: 0033059744     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-1-4419-8624-5_23     Document Type: Article

References (70)

1. Gottlieb TM, Oren M: p53 in growth control and neoplasia. Biochim Biophys Acta1287: 77-102, 1996
2. Ko LJ, Prives C: p53: Puzzle and paradigm. Genes Dev 10: 1054-1072, 1996
3. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997
4. Soussi T, May P: Structural aspects of the p53 protein in relation to gene evolution: A second look. J Mol Biol 260: 623-637, 1997
5. Jacks T, Weinberg RA: Cell-cycle control and its watchman. Nature 381: 643-644, 1996
6. Hall PA, Meek D, Lane DP: p53 - Integrating the complexity. J Path 1801-1805, 1996
7. Kastan MB, Onyelkwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991
8. Kastan MB, Zhan O, el Deiry W, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-957, 1992
9. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 491-495, 1992
10. Aloni GR, Schwartz D, Rotter V: Accumulation of wild-type p53 protein upon gammairradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO J 14: 1392-1401, 1995
11. Cross SM, Sanchez CA, Morgan CA, Schirnke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ: A p53-dependent mouse spindle checkpoint. Science 267: 353-356, 1995
12. Paules RS, Levedakou EN, Wilson SJ, Innes CL, Rhodes N, Tlsty TD, Galloway DA, Donehower LA, Tainsky MA, Kaufmann WK: Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res 55: 1763-1773, 1995
13. Yonish RE, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347, 1991
14. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J: Induction of apoptosis by wildtype p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89: 4495-4499, 1992
15. Lane DP: Cancer. A death in the life of p53 [news; comment]. Nature 362: 786-787, 1993
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991
17. Kinzler KW, Vogelstein B: Life (and death) in a malignant tumour. Nature 79: 19-20, 1996
18. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzier KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860, 1993
19. Finlay CA: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301-306, 1993
20. Chen J, Lin J, Levine AJ: Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1: 42-152, 1995
21. Chen X, Farmer G, Zhu H, Prywes R, Prives C: Cooperative DNA binding of p53 with TFIID (TBP): A possible mechanism for transcriptional activation [published erratum appears in Genes Dev 7: 2652, 1993]. Genes Dev 7: 1837-1849, 1993
22. Liu X, Miller CW, Koeffler PH, Berk AJ: The p53 activation domain binds the TATA boxbinding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol 3: 291-330, 1993
23. Lu H, Levine AJ: Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci USA 92: 5154-5158, 1995
24. Martin DW, Munoz RM, Subler MA, Deb S: p53 binds to the TATA-binding protein TATA complex. J Biol Chem 268: 3062-3067, 1993
25. Thut CJ, Chen JL, Klemm R, Tjian R: p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267: 100-104, 1995
26. Wang WW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly J-M, Wang Z, Friedberg EC, Evans MK, Taffe BG, Bohr VA, Weeda G, Hoeijmakers JHJ, Forrester K, Harris CC: p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genetics 10: 188-195, 1995
27. Dutta A, Ruppert JM, Aster JC, Winchester E: Inhibition of DNA-replication factor rpa by p53. Nature 365:79-82, 1993
28. He Z, Brinton BT, Greenblatt J, Hassell JA, Ingles CJ: The trans-activator proteins VP16 and GAL4 bind replication factor A. Cell 73: 1223-1232, 1993
29. Li R, Botchan MR: The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication. Cell 73: 1207-1221, 1993
30. Lane DP, Crawford LV: T-antigen is bound to host protein in SV40-transformed cells. Nature 278: 61-263, 1979
31. Linzer DI, Levine AJ: Characterization of a 54K daiton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52, 1979
32. Sarnow P, Ho YS, Williams J, Levine AJ: Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28: 387-394, 1982
33. Bakalkin G, Selivanova G, Yakovieva T, Kiseleva E, Kashuba E, Magnusson KP, Szekely L, Klein G, Terenius L, Wiman KG: p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res 23: 362-369, 1995
34. Jayaraman L, Prives C: Activation of p53 sequence-specific DNA binding by short single strand ends of DNA requires the p53 C-terminus. Cell 81: 1021-1029, 1995
35. Lee S, Elenbaas B, Levine A, Griffith J: p53 and its 14 kDa C-terminal domain recognise primary DNA damage in the form of insertion/ deletion mismatches. Cell 81: 1013-1020, 1995
36. Oberosler P, Hloch P, Ramsperger U, Stahl H: p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J 12: 2389-2396, 1993
37. Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F, Deppert W: Negative feedback regulation of wild-type p53 biosynthesis. EMBO J 14: 4442-4449, 1995
38. Walker KK, Levine AJ: Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93: 15335-15340, 1996
39. Meek DW: Post-translational modification of p53. Seminars in Cancer Biology 5: 203-210, 1994
40. Meek DW: Multisite phosphorylation and the integration of stress signals at p53. Cellular Signalling 10: 159-166, 1997
41. Meek DW, Simon S, Kikkawa U, Eckhart W: The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase 2. EMBO J 9: 253-3260, 1990
42. Herrmann CP, Kraiss S, Montenarh M: Association of casein kinase II with immunopurified p53. Oncogene 6: 877-884, 1991
43. Hupp TR, Meek DW, Midgley CA, Lane DP: Regulation of the specific DNA binding function of p53. Cell 71: 875-886, 1992
44. Mundt M, Hupp T, Merkle C, Hansen S, Lane D, Groner B: Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential. Oncogene 15: 237-244, 1997
45. Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G: Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem 271: 29380-29385, 1996
46. Filhoi-Cochet O, Loue-Mackenbach P, Cochet C, Chambaz EM: Casein kinase 2 and the cell response to growth factors. Cell Mol Biol Res 40: 529-537, 1994
47. Fiscella M, Zambrane N, Ullrich SJ, Unger T, Lin D, Cho B, Mercer WE, Anderson CW, Appella E: The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. Oncogene 9: 3249-3257, 1994
48. Crook T, Marston NJ, Sara EA, Vousden KH: Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79: 817-827, 1994
49. Fuchs B, Hecker D, Scheidtmann KH: p53 phosphorylation mutants retain transcription activity. Oncogene 10: 789-793, 1995
50. Hall SR, Campbell LE, Meek DW: Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res 24: 1119-1126, 1996
51. Milne DM, Palmer RH, Meek DW: Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. Nucleic Acids Res 20: 5565-5570, 1992
52. Filhol O, Baudier J, Chambaz EM, Cochet C: Casein kinase II inhibits the renaturation of complementary DNA strands mediated by p53 protein. Biochem J 316: 331-335, 1996
53. Litchfield DW, Dobrowolska G, Krebs EG: Regulation of casein kinase II by growth factors: A reevaluation. Cell Mol Biol Res 40: 373-381, 1994
54. McKendrick L, Meek DW: A novel system to investigate the phosphorylation of the p53 tumour suppressor protein by the protein kinase CK2. Cell Mol Biol Res 40: 555-561, 1994
55. Blochlinger K, Diggelmann H: Hygromycin B phosphotransferase as a selectable marker for DNA transfer experiments with higher eukaryotic cells. Mol Cell Biol 4: 2929-2931, 1984
56. Meek DW, Eckhart W: Mutation of the serine 312 phosphorylation site does not alter the ability of mouse p53 to inhibit simian virus 40 DNA replication in vivo. J Virol 64: 1734-1744, 1990
57. Meek DW, Eckhart W: Phosphorylation of p53 in normal and transformed simian virus 40-transformed NIH 3T3 cells. Mol Cell Biol 8: 461-465, 1988
58. Milne DM, Campbell DG, Caudwell FB, Meek DW: Phosphorylation of the tumour suppressor protein p53 by mitogen activated protein (MAP) kinases. J Biol Chem 269: 9253-9260, 1994
59. Krehan A, Lorenz P, Planacoll M, Pyerin W: Interaction sites between catalytic and regulatory subunits in human protein-kinase CK2 oloenzymes as indicated by chemical crosslinking and immunological investigations. Biochemistry 35: 4966-4975, 1996
60. Harlow E, Crawford LV, Pim DC, Williamson NM: Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol 39: 861-869, 1981
61. Barber JR, Verma IM: Modification of fos proteins: phosphorylation of c-fos, but not v-fos, is stimulated by 12-tetradecanoyl-phorbol-13-acetate and serum. Mol Cell Biol 7: 2201-2211, 1987
62. Shugar D: Development of inhibitors of protein kinases CK1 and CK2 and some related aspects, including donor and acceptor specificities and viral protein kinases. Cell Mol Biol Res 40: 411-420, 1994
63. Cohen P: The structure and regulation of protein phosphatases. Annu Rev Biochem 58: 453-508, 1989
64. MacKintosh C, MacKintosh RW: Inhibitors of protein-kinases and phosphatases. Trends Biochem Sei 19: 444-448, 1994
65. Scheidtmann KH, Mumby MC, Rundell K, Waiter G: Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: Inhibition by small-t antigen. Mol Cell Biol 11: 1996-2003, 1991
66. Krek W, Maridor G, Nigg EA: Casein kinase II is a predominantly nuclear enzyme. J Cell Biol 16(1): 43-55, 1992
67. Hupp TR, Lane DP: Allosteric activation of latent p53 tetramers. Curr Biol 4: 865-875, 1994
68. Iwabuchi K, Li B, Bartei P, Fields S: Use of the two-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene 8: 1693-1696, 1993
69. Helps NR, Barker HM, Elledge SJ, Cohen PTW: Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumour supressor p53. FEBS Lett 377: 295-300, 1995
70. Milne DM, Campbell L, Campbell DG, Meek DW: p53 is phosphorylated in vitro and in vivo by an ultra-violet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK-1. J Biol Chem 270: 5511-5518, 1995